UBS Group AG Raises Stock Holdings in Palvella Therapeutics, Inc. $PVLA

UBS Group AG grew its stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 78.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,505 shares of the company’s stock after acquiring an additional 16,066 shares during the quarter. UBS Group AG’s holdings in Palvella Therapeutics were worth $3,821,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at $36,000. JPMorgan Chase & Co. lifted its position in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Palvella Therapeutics in the second quarter valued at $85,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Palvella Therapeutics in the second quarter valued at $104,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on PVLA shares. Stifel Nicolaus set a $250.00 price objective on Palvella Therapeutics in a research report on Tuesday, February 24th. Truist Financial set a $210.00 price objective on Palvella Therapeutics in a research report on Tuesday, February 24th. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. HC Wainwright upped their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, BTIG Research upped their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Palvella Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Trading Down 1.7%

NASDAQ PVLA opened at $113.99 on Friday. The business’s 50-day moving average price is $121.93 and its 200 day moving average price is $105.45. Palvella Therapeutics, Inc. has a twelve month low of $20.20 and a twelve month high of $151.18. The company has a market capitalization of $1.63 billion, a PE ratio of -27.34 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Equities analysts predict that Palvella Therapeutics, Inc. will post -5.43 EPS for the current year.

Insider Buying and Selling

In other Palvella Therapeutics news, Director Elaine J. Heron bought 2,400 shares of Palvella Therapeutics stock in a transaction that occurred on Friday, February 27th. The shares were purchased at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. This represents a 5.28% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is currently owned by company insiders.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.